Payment overview · 2025
General Payments
$349.19
3 reported records · 2 companies
Healthcare provider profile · identity verified
Nicholas Hamner Tuttle, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCK HILL, SC · NPI 1447251186
Verified facts
What the public records show
CMS Open Payments records show Nicholas Hamner Tuttle, MD received $349.19 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.72 | 69.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $107.47 | 30.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.19 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $107.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 455 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 111 |
| Gabapentin | Gabapentin | 330 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 253 | 81 |
| Tramadol Hcl | Tramadol Hcl | 235 | 44 |
| Metformin Hcl Er | Metformin Hcl | 233 | 71 |
| Sertraline Hcl | Sertraline Hcl | 232 | 58 |
| Losartan Potassium | Losartan Potassium | 231 | 72 |
| Trazodone Hcl | Trazodone Hcl | 227 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 29 |
| Metformin Hcl | Metformin Hcl | 167 | 49 |
| Allopurinol | Allopurinol | 157 | 49 |
| Lisinopril | Lisinopril | 153 | 45 |
| Potassium Chloride | Potassium Chloride | 146 | 47 |
| Simvastatin | Simvastatin | 141 | 44 |
| Famotidine | Famotidine | 139 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 55 |
| Methylprednisolone | Methylprednisolone | 131 | 98 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 29 |
| Synthroid | Levothyroxine Sodium | 95 | 26 |
| Alprazolam | Alprazolam | 92 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 27 |
| Bupropion Xl | Bupropion Hcl | 84 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 19 |
| Clonazepam | Clonazepam | 77 | 13 |
| Farxiga | Dapagliflozin Propanediol | 76 | 17 |
| Ozempic | Semaglutide | 73 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 11 |
| Irbesartan | Irbesartan | 62 | 15 |
| Azithromycin | Azithromycin | 61 | 54 |
| Ipratropium Bromide | Ipratropium Bromide | 60 | 26 |
| Montelukast Sodium | Montelukast Sodium | 60 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 21 |
| Buspirone Hcl | Buspirone Hcl | 57 | 22 |
| Estradiol | Estradiol | 56 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Pregabalin | Pregabalin | 55 | 14 |
| Valsartan | Valsartan | 52 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 24 |
| Valacyclovir | Valacyclovir Hcl | 49 | 16 |
| Finasteride | Finasteride | 48 | 15 |
| Meloxicam | Meloxicam | 48 | 15 |
| Eliquis | Apixaban | 46 | 14 |
| Prednisone | Prednisone | 46 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 13 |
| Ibuprofen | Ibuprofen | 44 | 16 |
| Lansoprazole | Lansoprazole | 44 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 18 |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Celecoxib | Celecoxib | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Verapamil Er | Verapamil Hcl | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Furosemide | Furosemide | 33 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 14 |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Torsemide | Torsemide | 25 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 18 |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 21 | 11 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Triazolam | Triazolam | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Minoxidil | Minoxidil | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Carvedilol | Carvedilol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.19 · 3 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error